Cencora Outlines Specialty Growth Strategy, Expands MSO Operations, and Reinforces Walgreens Partnership
During a recent investor conference, Cencora emphasized its growth strategy centered on specialty pharmaceuticals and Medical Specialty Organizations (MSOs), particularly in retina and oncology practices. The company expects the MSO segment to remain profitable while expanding through physician partnerships and tuck-in acquisitions. Management also highlighted World Courier's role in supporting clinical trials but ruled out acquiring a contract research organization, instead positioning its logistics capabilities as complementary to pharmaceutical manufacturers. Cencora reaffirmed its capital-allocation priorities: core investments, smaller acquisitions, share repurchases, dividend growth aligned with earnings, and maintaining financial strength. The company also confirmed the durability of its partnership with Walgreens under long-term contracts set for 2029 in the U.S. and through 2031 via Boots. CEO Bob Mauch attributed Cencora's positioning to decades of investment in specialty care services and innovation within pharmaceuticals, while new CFO Eva Boratto praised the company’s strategic clarity and breadth of service offerings.
Tickers: $COR
Topics: capital allocation MSO expansion specialty pharmaceuticals Walgreens partnership